CRISPR
(clustered, regularly interspaced, short palindromic repeats)
has become a cutting-edge research method and holds great potential
to revolutionize biotechnology and medicine. However, like other nucleic
acid technologies, CRISPR will greatly benefit from chemical innovation
to improve activity and specificity for critical in vivo applications.
Chemists have started optimizing various components of the CRISPR
system; the present Perspective focuses on chemical modifications
of CRISPR RNAs (crRNAs). As with other nucleic acid-based technologies,
early efforts focused on well-established sugar and backbone modifications
(2′-deoxy, 2′-F, 2′-OMe, and phosphorothioates).
Some more significant alterations of crRNAs have been done using bicyclic
(locked) riboses and phosphate backbone replacements (phosphonoacetates
and amides); however, the range of chemical innovation applied to
crRNAs remains limited to modifications that have been successful
in RNA interference and antisense technologies. The encouraging results
given by these tried-and-true modifications suggest that, going forward,
chemists should take a bolder approachresearch must aim to
investigate what chemistry will have the most impact on maturing CRISPR
as therapeutic and other in vivo technologies. With an eye to the
future, this Perspective argues that the complexity of CRISPR presents
rich unprecedented opportunities for chemists to synergize advances
in synthetic methodology and structural biochemistry to rationally
optimize crRNA–protein interactions.